Production of SARS-CoV-2 Antibodies and Emergence of the Clinical Symptoms of COVID-19

Ahmad Hormati; Hossein Poustchi; Mohammad Reza Ghadir; Saeede Jafari; Narges Jafari; Abdolreza Ashtari; Sajjad Ahmadpour

doi:10.18502/ijaai.v20i2.6057

Ahmad Hormati Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
Hossein Poustchi Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Reza Ghadir Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran
Saeede Jafari Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
Narges Jafari Health center, Qom University of Medical Sciences, Qom, Iran
Abdolreza Ashtari Constituent and Technical in Charge of Kimia Pathological and Medical Laboratory, Qom, Iran
Sajjad Ahmadpour Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran

DOI: https://doi.org/10.18502/ijaai.v20i2.6057

Keywords: Antibodies; COVID-19; Diagnosis; Polymerase chain reaction

Abstract

Coronavirus disease 2019 (COVID-19) is a worldwide public health problem that has attracted much attention due to its clinical findings. Measurement of IgG and IgM antibodies is of great importance for researchers and it will help to develop a new diagnostic and therapeutic method in clinical care. In this cross-sectional study, we aim to measure the IgG and IgM antibody levels in 401 suspected COVID-19 volunteers. We also measure the time duration for the appearance of IgG and IgM antibodies from the onset of symptoms to sampling time. Of 401 participants enrolled in the study, 255 (63.59%) were healthy, 79 (19.70%) were a carrier, 59 (14.71%) were cured and 8 (1.99%) were borderline. Of 142 subjects diagnosed with COVID-19, 41 (28.87%) presented with gastrointestinal (GI) symptoms, 83 (58.45%) had no GI symptoms, and 18 (12.68%) were asymptomatic. According to our findings, the measurement of IgG and IgM antibodies will provide the tool for the diagnosis of COVID-19 and significantly boost research into novel diagnostic and therapeutic approaches.